SYMBIO PHARMACEUTICALS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 172 JPY | -1.15% |
|
-4.44% | -30.36% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
SymBio Pharmaceuticals Limited is a Japan-based pharmaceutical company. Along with medicine specialists, contract research organizations (CROs) and other pharmaceutical companies, the Company is engaged in the design and operation of clinical tests, the manufacture and sale of new drugs specializing in three therapeutic areas: cancer, blood diseases and autoimmune diseases. The Company develops new medicines using chemical compounds proofed by preclinical tests and clinical tests. The Company manufactures and sells medicines through domestic and foreign pharmaceutical companies. The Company's pipelines include anticancer drugs, such as SyB L-0501, SyB L-1101 and SyB C-1101.
Sector
Pharmaceuticals
Calendar
2024-05-06
- Q1 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -30.36% | 50.57M | |
| +33.25% | 699B | |
| +25.31% | 571B | |
| -3.55% | 364B | |
| +18.16% | 326B | |
| +4.36% | 286B | |
| +14.94% | 236B | |
| +5.48% | 198B | |
| -9.37% | 194B | |
| -3.69% | 149B |
- Stock Market
- Equities
- 4582 Stock
- News SymBio Pharmaceuticals Limited
- SymBio Pharmaceuticals Adjusts Forecasts to Reflect Shrinking Market Demand
